

NOTICE: This is a translation of a notice in Japanese issued on June 24, 2025 and is made solely for the convenience of foreign shareholders. In case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536  
June 24, 2025

**RESOLUTION NOTICE  
OF THE 113<sup>TH</sup> ANNUAL GENERAL MEETING OF SHAREHOLDERS  
OF SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, at the 113<sup>th</sup> Annual General Meeting of Shareholders of the Company that was held today.

Very truly yours,

Takeshi Ito  
Representative Director, President & CEO  
SANTEN PHARMACEUTICAL CO., LTD.  
4-20, Ofuka-cho, Kita-ku, Osaka, Japan

**Reports:**

1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 113<sup>th</sup> Business Term (April 1, 2024 to March 31, 2025)
2. Report on the Audit Reports of the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 113<sup>th</sup> Business Term (April 1, 2024 to March 31, 2025)

As regards the items set forth above, the contents thereof were reported.

**Resolved Items:****Proposal No. 1: Appropriation of Surplus**

As to this item, the term-end dividends of profits were resolved to be JPY 19 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed, are at JPY 36 per share.

As to the appropriation of surplus, JPY 50.0 billion was resolved to be withdrawn from the general reserve and transferred to retained earnings brought forward.

**Proposal No. 2: Appointment of Six (6) Directors**

As regards this item, Takeshi Ito, Rie Nakajima, Ippei Kurihara, Masahiko Ikaga, Minoru Kikuoka and Yukiko Kuroda were appointed as Directors as per the original proposal; each of them assumed his or her office.

Masahiko Ikaga, Minoru Kikuoka and Yukiko Kuroda are Outside Directors.

**Proposal No. 3: Revision of the Limit of Monetary Remuneration for Directors Excluding Outside Directors**

As regards this item, the limit of monetary remuneration for Directors excluding Outside Directors was revised to no more than JPY 700 million per year (of which no more than JPY 400 million shall continue to be the basic compensation, and no more than JPY 300 million shall be the annual bonus) as per the original proposal.

**Proposal No.4: The Partial Revision of the Stock-Based Remuneration Program for Directors Excluding Outside Directors**

As regards this item, the revision of the program for Directors excluding Outside Directors (the “Target Directors”) was resolved as per the original proposal, in which the upper limit of remuneration relating to the Performance Share Unit System (a post-delivery type performance-linked stock remuneration system) for the Target Directors shall be raised and the performance evaluation indicators shall be changed, as well as the current Restricted Stock-Based Remuneration System shall be abolished and the Restricted Stock Unit System (a post-delivery type stock-based remuneration system) shall be introduced for the Target Directors.

## ANNOUNCEMENT

At the Board of Directors' meeting, which was held after the close of this Annual General Meeting of Shareholders, Takeshi Ito was appointed as Representative Director, President and CEO. He assumed the said office.

As a result thereof, the Directors and Corporate Auditors of the Company shall be as follows:

### Directors and Corporate Auditors

Takeshi Ito	Representative Director President, Chief Executive Officer
Rie Nakajima	Director Corporate Officer, Chief Operating Officer
Ippei Kurihara	Director Corporate Officer
Masahiko Ikaga*	Director
Minoru Kikuoka*	Director
Yukiko Kuroda*	Director
Hiroshi Isaka	Standing Corporate Auditor
Junichi Asatani**	Corporate Auditor
Yaeko Hodaka**	Corporate Auditor
Yuichiro Munakata**	Corporate Auditor

\* The Outside Directors (indicated by an asterisk (\*) next to their names) are Independent Officers (as set forth in Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply.).

\*\* The Outside Corporate Auditors (indicated by two asterisks (\*\*)) next to their names) are Independent Officers.

End.